Regeneron Pharmaceuticals, Inc. REGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 35.14% | 17.35% | 16.54% | 0.99% | -1.40% |
| Total Other Revenue | 56.41% | 5.11% | 109.04% | 33.00% | 73.56% |
| Total Revenue | 36.27% | 16.73% | 19.04% | 2.51% | 0.90% |
| Cost of Revenue | 18.62% | 13.13% | 23.51% | 11.79% | 13.28% |
| Gross Profit | 56.31% | 20.82% | 12.57% | -7.62% | -10.23% |
| SG&A Expenses | 3.04% | 4.40% | 2.32% | -2.17% | -7.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.19% | 10.99% | 17.98% | 7.80% | 6.76% |
| Operating Income | 86.48% | 30.38% | 23.31% | -11.86% | -10.76% |
| Income Before Tax | 29.54% | 0.60% | -8.15% | 8.93% | 18.10% |
| Income Tax Expenses | 10.58% | 81.67% | 8.00% | 392.82% | 99.02% |
| Earnings from Continuing Operations | 33.47% | -6.81% | -10.08% | -7.97% | 8.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.47% | -6.81% | -10.08% | -7.97% | 8.91% |
| EBIT | 86.48% | 30.38% | 23.31% | -11.86% | -10.76% |
| EBITDA | 75.73% | 26.10% | 18.76% | -8.93% | -8.70% |
| EPS Basic | 35.97% | -4.72% | -7.74% | -3.76% | 13.64% |
| Normalized Basic EPS | 80.28% | 27.36% | 19.84% | 77.68% | -6.94% |
| EPS Diluted | 35.46% | -4.53% | -7.15% | -2.64% | 18.02% |
| Normalized Diluted EPS | 79.66% | 27.63% | 20.61% | 79.88% | -3.32% |
| Average Basic Shares Outstanding | -1.83% | -2.19% | -2.53% | -4.37% | -4.16% |
| Average Diluted Shares Outstanding | -1.49% | -2.39% | -3.15% | -5.54% | -7.75% |
| Dividend Per Share | 6.82% | 6.82% | 6.82% | -- | -- |
| Payout Ratio | -0.21% | 0.12% | 0.16% | -- | -- |